Animax Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 05-12-2024
- Paid Up Capital ₹ 2.50 M
as on 05-12-2024
- Company Age 17 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.00 M
as on 05-12-2024
- Satisfied Charges ₹ 3.00 M
as on 05-12-2024
- Revenue 13.31%
(FY 2022)
- Profit -10.90%
(FY 2022)
- Ebitda -28.32%
(FY 2022)
- Net Worth 51.81%
(FY 2022)
- Total Assets 34.02%
(FY 2022)
About Animax Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹8.00 M. The company has closed loans amounting to ₹3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Bijender Kumar and Meena Kumari serve as directors at the Company.
- CIN/LLPIN
U85120DL2007PTC157251
- Company No.
157251
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jan 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Animax Pharma Private Limited offer?
Animax Pharma Private Limited offers a wide range of products and services, including Animal Medicines & Health Care, Veterinary Medicines, Bird Food, Poultry & Animal Food, Animal Feed Supplement.
Who are the key members and board of directors at Animax Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bijender Kumar  | Director | 02-Jan-2007 | Current |
| Meena Kumari | Director | 05-Feb-2011 | Current |
Financial Performance of Animax Pharma.
Animax Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 13.31% increase. The company also saw a substantial fall in profitability, with a 10.9% decrease in profit. The company's net worth Soared by an impressive increase of 51.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Animax Pharma?
In 2021, Animax Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 08 Feb 2017 | ₹8.00 M | Open |
Sarva Haryana Gramin Bank Creation Date: 15 Jan 2015 | ₹3.00 M | Satisfied |
How Many Employees Work at Animax Pharma?
Animax Pharma has a workforce of 223 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Animax Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Animax Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
